文献速递心力衰竭与心肌病

种族/族裔类别与心肌病基因检测检出能力的关联

Association of Racial/Ethnic Categories With the Ability of Genetic Tests to Detect a Cause of Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2018-01-01

白人致病/可能致病变异检出率为29.0%,显著高于代表性不足少数族裔的18.4%(P<.001);白人意义不明确结果比例为24.6%,显著低于代表性不足少数族裔的39.8%(P<.001)。

要点

  • 白人先证者心肌病基因检测阳性检出率显著高于代表性不足少数族裔。
  • 白人先证者意义不明确结果比例显著低于代表性不足少数族裔和亚裔。
  • 该差异提示基因检测对白人心肌病的临床实用性更高,需进一步研究。

核心结论

  • 白人个体心肌病基因检测的阳性检出率显著高于代表性不足少数族裔,意义不明确结果比例显著更低。
  • 这提示基因检测对白人心肌病的临床实用性高于其他种族/族裔群体。

研究设计与样本

  • 检测在马萨诸塞州剑桥市Partners个性化医学分子医学实验室完成,按自我报告种族/族裔分为白人、亚裔和代表性不足少数族裔。

主要发现

  • 白人阳性检出1314例(29.0%),代表性不足少数族裔155例(18.4%;χ21=39.8;P<.001),亚裔87例(25.0%;χ21=2.5;P=.12)。
  • 白人意义不明确结果1115例(24.6%),代表性不足少数族裔335例(39.8%;χ21=83.6;P<.001),亚裔136例(39.2%;χ21=35.8;P<.001)。
  • 5729例先证者中男性3523例(61.5%),白人4539例(79.2%),亚裔348例(6.1%),代表性不足少数族裔842例(14.7%)。

临床怎么用

  • 临床解读心肌病基因检测结果时,应考虑种族/族裔间阳性检出率和意义不明确结果比例的差异。
  • 对代表性不足少数族裔患者,意义不明确结果比例较高可能影响基因检测的临床决策价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Individuals of all races/ethnicities have a fundamental right to access health care and benefit from advances in science and medicine, including genetic testing. OBJECTIVE: To determine whether detection rates for cardiomyopathy genetic testing differed between white people, Asian people, and underrepresented minorities (individuals of black, Hispanic, Native American, Alaskan Native, or Pacific Islander descent). DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional analysis of the genetic panel test results of 5729 probands who had a suspected diagnosis or family history of cardiomyopathy and who had been referred for testing between October 2003 and December 2017. Testing was performed at the Laboratory for Molecular Medicine at Partners Personalized Medicine in Cambridge, Massachusetts. Results were stratified into 3 categories of self-reported race/ethnicity: white, Asian, and underrepresented minorities. MAIN OUTCOMES AND MEASURES: The primary outcome was whether a pathogenic or likely pathogenic variant was identified that explained the features or family history of cardiomyopathy. A secondary outcome was the number of test results that were inconclusive because of the presence of 1 or more variants of uncertain significance in the absence of an explanation for cardiomyopathy features or family history. RESULTS: A total of 5729 probands were studied (of whom 3523 [61.5%] were male). Of these, 4539 (79.2%) were white, 348 (6.1%) were Asian individuals, and 842 (14.7%) were underrepresented minorities. Positive detection occurred in 1314 white individuals (29.0%) compared with 155 underrepresented minorities (18.4%; χ21 = 39.8; P < .001) and 87 Asian individuals (25.0%; χ21 = 2.5; P = .12). Inconclusive results were found in 1115 white individuals (24.6%) compared with 335 underrepresented minorities (39.8%; χ21 = 83.6; P < .001) and 136 Asian individuals (39.2%; χ21 = 35.8; P < .001). CONCLUSIONS AND RELEVANCE: These results show a significantly higher positive detection rate and a significantly lower rate of inconclusive results in white individuals in comparison with underrepresented minorities. This suggests greater clinical usefulness of genetic testing for cardiomyopathy in white persons in comparison with people of other racial/ethnic groups. This clear disparity warrants further study to understand the gaps in usefulness, which may derive from a lack of clinical testing and research in underrepresented minority populations, in the hopes of improving genetic testing outcomes for cardiomyopathy in nonwhite groups.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Landry LG, Rehm HL. Association of Racial/Ethnic Categories With the Ability of Genetic Tests to Detect a Cause of Cardiomyopathy. JAMA Cardiol. 2018. PMID: 29490334. doi:10.1001/jamacardio.2017.5333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。